/Investor DB

Qiming Venture Partners — 2019 Investments

4 investments dated 2019 · listed companies and verified rows first · show all

Korro Biokorrobio.comin𝕏NASDAQ: KRROMay 2019

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.

BiotechHealthtechCambridge, US

Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)inJean-François Formela(Director)inOmmer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)inRam Aiyar(Chief Executive Officer, President and Director)inTodd Chappell(Chief Operating Officer)in

Co-investorsAtlas VentureMC Healthcare VenturesNew Enterprise Associates (NEA)AlexandriaQiming Venture Partners USARock Springs Capital+3 more

Insilico Medicineinsilico.comin𝕏Sep 2019✓ verified

Insilico Medicine uses artificial intelligence to discover and develop new drugs, operating an AI-driven platform for pharmaceutical research and development.

AI & Machine LearningBiotechDigital HealthHealthtechHong Kong, US

Aleksandrs Zavoronkovs(Executive Officer, Director)Alex Zavoronkov(Director)Alex Zhavoronkov(Founder)inAlex Aliper(President)inFeng Ren(Chief Scientific Officer, Executive Director & Co-CEO)in

BoardNisa Leung(Director)in

Co-investorsLilly Asia VenturesOrbiMedWarburg PincusBaidu VenturesEight Roads VenturesLake Bleu Capital+16 more

Antengeneantengene.comJan 2019 · $120M

Antengene is a biopharmaceutical company that develops therapies for cancer, with a pipeline focused on hematologic malignancies and solid tumors including Claudin 18.2, CD73, PD-L1/4-1BB bispecific, and CD24-targeting candidates.

BiotechHealthtech

Jay Mei(Founder)

Co-investorsDecheng CapitalBoyu CapitalFountainVest Partners

Haoyikuhaoyiku.com.cnSep 2019

Haoyiku is a private-domain e-commerce brand flash-sale platform in China that provides brand supply-chain and discounted-sales services to private-domain traffic operators such as resellers and shop owners.

B2B MarketplacesE-commerceRetail TechHangzhou, CN

Co-investorsIDG CapitalK2VCSky9 CapitalTencent HoldingsVision Plus Capital

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.